GBD-209

N/A

Report date: 2025/03/03 15:37:08

Base Information

Drug NameGBD-209
Drug Alias NameGBD-209GBD209
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-PD-1Anti-CTLA4Anti-T cell immunoglobulin and ITIM domains
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4T cell immunoglobulin and ITIM domains
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenor Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGenor Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A